0:00

So, this was a patient that had left-sided

0:02

breast cancer and was treated with

0:04

high-dose chemotherapy and radiation therapy.

0:06

So, again, the abnormality was on the left side.

0:09

So, again, when I start looking at the

0:10

brachial plexus, the first thing that I

0:12

have to do is look at the normal side.

0:14

So, on the right-hand side, we can see the

0:16

normal appearance of the subclavian artery,

0:18

and right above this, we can see the cords

0:21

of the brachial plexus right below it.

0:23

So, we can see that they are nice and thin.

0:25

We can see a nice fat stripe between

0:27

the superior portion of the subclavian

0:29

artery and the inferior portion of

0:30

the cords of the brachial plexus.

0:32

Now, when we scroll and we start looking

0:34

at the left side, what we end up seeing

0:36

is that we can see the subclavian

0:38

artery, but notice the brachial plexus.

0:40

Notice how the brachial plexus is

0:42

diffusely thickened, and there's not

0:44

really a definable mass, rather, it's

0:46

just, again, diffusely thickened, and I

0:49

use the term it's almost glued together.

0:52

And then when I look at the STIR

0:54

sequences, what we see here is that

0:56

there's actually abnormal signal. Again,

0:58

involving the cords of the brachial

0:59

plexus on the left compared to the right.

1:02

So, we see the normal STIR signal on the left.

1:05

Now, on the far-right image, again,

1:07

this is a sequence that's optimized

1:10

to look at the nerves themselves.

1:12

And again, we can see very nice

1:13

clarity of some of the exiting

1:15

nerve roots from the spinal canal.

1:17

But when we look at the brachial plexus on the

1:19

left, again, we see diffuse abnormal thickening

1:22

and abnormal enhancement of the brachial

1:24

plexus in the high-dose radiation field.

1:28

So this is an example, again, of radiation

1:30

associated brachial plexopathy due

1:33

to a neuritis that is associated with

1:36

the radiation therapy that was given

1:39

in this patient with breast cancer.